New York Medical College
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, New York Medical College sits in the top decile of US sponsors by registered trial count (#390 of 15,742 sponsors by registered trial count).
New York Medical College: 47 sponsored US clinical trials, 16 recruiting.
New York Medical College sponsors 47 registered US clinical trials on ClinicalTrials.gov, 16 of them currently recruiting, and 19 completed. 1 of these trials are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Immune Deficiency Disorder, with 4 trials.
Top-decile sponsor footprint
New York Medical College ranks in the top decile of sponsors by registered trial count (#390 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 27 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
47 total, page 1 of 1
Defibrotide Dose-escalation for SOS Post-HSCT
NCT05987124
CMV CTLs in Neonates With CMV Infection
NCT05564598
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
NCT04972942
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
NCT05253495
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease
NCT04896606
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
NCT04491370
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
NCT04323748
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
NCT03266653
Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)
NCT04197596
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
NCT03719105
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
NCT03266640
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
NCT03266627
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
NCT02675959
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
NCT04308330
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
NCT02393157
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
NCT02249923
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
NCT07013565
Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease
NCT01461837
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
NCT06617286
Combined Aphasia and Robot-Assisted Arm Treatment for Chronic Stroke Survivors
NCT07000019
Participating in T'ai Chi to Reduce Back Pain and Improve Quality of Life
NCT05801588
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
NCT04478474
To Evaluate the Outcomes After Surgery for Necrotizing Soft Tissue Infections
NCT05032625
The Effect of Platelet-rich Fibrin Matrix on Skin Rejuvenation
NCT04128046
Randomized Control Trial: Synchronized Non-invasive Positive Pressure Ventilation Versus Non Synchronized Non Invasive Positive Pressure Ventilation in Extremely Low Birth Weight Infants
NCT03613987
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
NCT03805581
Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS
NCT03261570
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
NCT04041843
Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)
NCT02558972
ODSH + ICE Chemotherapy in Pediatric Solid Tumors
NCT02164097
In Vitro Fertilization and Pregnancy After Use of Chemotherapy
NCT00520364
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
NCT02057445
Human Placental-Derived Stem Cell Transplantation
NCT01586455
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
NCT01842672
Effect of Tetrabenazine on Stroop Interference in HD
NCT01834911
Mechanisms of Vasovagal Syncope
NCT01791816
Treatment for Advanced B-Cell Lymphoma
NCT01859819
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
NCT01636388
SCT Plus Immune Therapy in Average Risk AML/MDS
NCT02117297
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
NCT02221310
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
NCT01049854
Local Vasoconstriction in Postural Tachycardia Syndrome
NCT01210430
EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance
NCT00618072
Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
NCT00684255
Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL
NCT00529360
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML
NCT00669890
Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients
NCT00504699
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 19 |
| Phase 4 | 1 |
What is open in the New York Medical College pipeline
16 recruiting of 47 indexed (34% open); 19 completed (40%).
Phase mix: 1 late (III/IV) vs 37 early (I/II) (early-phase heavy).
Top condition: Primary Immune Deficiency Disorder (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
New York Medical College: open-pipeline peers nationwide
Peers matched on 47 registered trials and 34% open enrollment, not the therapeutic-area sidebar.
New York Medical College sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 47 trials (± recruiting share)
- PepsiCo Global R&D · 47 trials · 32% recruiting
- USDA, Western Human Nutrition Research Center · 47 trials · 2% recruiting
- Albert Einstein Healthcare Network · 48 trials · 6% recruiting
- Exelixis · 48 trials · 17% recruiting
Sponsors near 34% open enrollment (± trial volume)
- The University of Texas at Arlington · 34% recruiting · 32 trials
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
Related
What to do with this New York Medical College page
47 registered trials is a research-attention snapshot, not an endorsement of New York Medical College or any single study.
- 16 of New York Medical College's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Primary Immune Deficiency Disorder is the condition New York Medical College studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Immune Deficiency Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
New York Medical College pipeline card: 47 registered trials from official public datasets.Report a data error.